A Phase 1 interventional study of VXCO-102 and Placebo in EBV, sponsored by Vaccine Company, Inc, a wholly owned subsidiary of Eli Lilly and Company. Recruiting at 2 sites in Australia. Open to participants aged 18 Years to 25 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by Vaccine Company, Inc, a wholly owned subsidiary of Eli Lilly and Company (part of Eli Lilly and Company) · Phase 1, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Epstein-Barr Virus Infections with a site in Australia — 3 open to participants now, 5 under way, 2 of them phase 3. Epstein-Barr Virus Infections · Australia.
Among the 10 studies in Epstein-Barr Virus Infections with a site in Australia, this one is one of 3 that started in 2026, is one of 4 in phase 1, and was the 10th registered.
175 studies on the registry are indexed under Epstein-Barr Virus Infections; 60 are open to participants now.
Browse Epstein-Barr Virus Infections studies →3 of the 10 studies in Epstein-Barr Virus Infections with a site in Australia are open now. Recruiting first, the newest first:
ModernaTX, Inc. · Sites in Australia
Ages 18–30 · Healthy volunteers
Pierre Fabre Medicament · Sites in Australia, United States, Austria and 6 more countries
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 43 Epstein-Barr Virus Infections studies recruiting now, 23 (53%) set no upper age limit and 16 (37%) stop at 75 or younger; 23 take children under 18; 6 take healthy volunteers.
This study: 18 Years to 25 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 4 · Phase 3 3
First in 2008; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 82 is above the median of 28 across 114 interventional studies indexed under Epstein-Barr Virus Infections.
Median enrollment 115 across the 9 interventional studies, 100 across the 1 observational. Of the 5 that completed or were terminated, 2 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 10 have an industry lead sponsor. The 9 most frequent:
This study is registered under Vaccine Company, Inc, a wholly owned subsidiary of Eli Lilly and Company, one of the names counted as Eli Lilly and Company. Under that name alone:
This is the only study on the registry with Vaccine Company, Inc, a wholly owned subsidiary of Eli Lilly and Company as lead sponsor.
Eli Lilly and Company has 1 study filed under Epstein-Barr Virus Infections — fewer than ten, so there is no comparison to draw.
2 of the studies in Epstein-Barr Virus Infections with a site in Australia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07536048Sanofi Pasteur, a Sanofi CompanyA Longitudinal Study of Epstein-Barr Virus (EBV) Reactivation in Adults Aged 18 to 29 Years | 2027-05-14 |
| NCT07478952ModernaTX, Inc.A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189 in Healthy Adults 18 to 30 Years of Age | 2027-05-15 |
Add all 2 to your calendar (.ics) → With an account.
Among the 10 studies in Epstein-Barr Virus Infections with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 1 clinical trial to evaluate the safety and immunogenicity of VXCO-102 in healthy adult participants.
This first-in-human, dose-escalation Phase 1 trial evaluates the safety, tolerability, and immunogenicity of VXCO-102 in healthy young adults across multiple sites in Australia.
The trial will enroll up to 90 participants aged 18-25. After sentinel safety review in each dose cohort, participants will be randomized to receive VXCO-102 or placebo, with a booster at Week 8.
All participants will undergo ongoing safety monitoring and immune response assessments through clinical evaluations, sample collection, and participant reporting.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Note: Other inclusion and exclusion criteria apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dose 1 - VXCO-102 administered IM by needle and syringe at Day 1 and Week 8
Biological: VXCO-102
Dose 2 - VXCO-102 administered IM by needle and syringe at Day 1 and Week 8
Biological: VXCO-102
Dose 3 - VXCO-102 administered IM by needle and syringe at Day 1 and Week 8
Biological: VXCO-102
Sodium Chloride administered IM by needle and syringe at Day 1 and Week 8
Biological: Placebo
Sterile liquid for injection
0.9% sodium chloride (BP grade)
Number of Participants with Solicited Local and Systemic Reactions
Time frame: 7 days after each product administration
Number of Participants with Unsolicited Adverse Events
Time frame: Up to 28 days after each product administration
Number of Participants with Serious Adverse Events (SAEs) including Suspected Unexpected Serious Adverse Reactions (SUSARs) and Adverse Events of Special Interest (AESIs)
Time frame: Day 1 to end of study (Day 357)
Rate and Magnitude of Neutralizing Antibody Responses
Time frame: Day 1 and 85
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Feb 2028, 15 months later.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 26, 2026: start May 2026 → Nov 2026, primary completion Aug 2027 → Feb 2028 and completion Aug 2027 → Feb 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Epstein-Barr Virus Infections →